SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Carmen Farinas Maria)
 

Sökning: WFRF:(Carmen Farinas Maria) > Propensity Score an...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00010066naa a2200925 4500
001oai:DiVA.org:uu-470107
003SwePub
008220321s2021 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4701072 URI
0247 a https://doi.org/10.1128/AAC.01102-212 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Gutierrez-Gutierrez, Belenu Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Seville, Virgen Macarena Univ Hosp, Inst Biomed Seville, Clin Unit Infect Dis & Microbiol, Seville, Spain.4 aut
2451 0a Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-Producing Enterobacterales in Kidney Transplant Recipients
264 1b American Society for Microbiology,c 2021
338 a print2 rdacarrier
520 a There are scarce data on the efficacy of ertapenem in the treatment of bacteremia due to extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales (ESBL-E) in kidney transplant (KT) recipients. We evaluated the association between treatment with ertapenem or meropenem and clinical cure in KT recipients with nonsevere bacteremic urinary tract infections (B-UTI) caused by ESBL-E. We performed a registered, retrospective, international (29 centers in 14 countries) cohort study (INCREMENT-SOT, NCT02852902). The association between targeted therapy with ertapenem versus meropenem and clinical cure at day 14 (the principal outcome) was studied by logistic regression. Propensity score matching and desirability of outcome ranking (DOOR) analyses were also performed. A total of 201 patients were included; only 1 patient (treated with meropenem) in the cohort died. Clinical cure at day 14 was reached in 45/100 (45%) and 51/101 (50.5%) of patients treated with ertapenem and meropenem, respectively (adjusted OR 1.29; 95% CI 0.51 to 3.22; P = 0.76); the propensity score-matched cohort included 55 pairs (adjusted OR for clinical cure at day 14, 1.18; 95% CI 0.43 to 3.29; P = 0.74). In this cohort, the proportion of cases treated with ertapenem with better DOOR than with meropenem was 49.7% (95% CI, 40.4 to 59.1%) when hospital stay was considered. It ranged from 59 to 67% in different scenarios of a modified (weights-based) DOOR sensitivity analysis when potential ecological advantage or cost was considered in addition to outcome. In conclusion, targeted therapy with ertapenem appears as effective as meropenem to treat nonsevere B-UTI due to ESBL-E in KT recipients and may have some advantages.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng
653 a ertapenem
653 a extended-spectrum-beta-lactamase-producing Enterobacterales
653 a ESBL-E
653 a urinary tract infection
653 a UTI
653 a bloodstream infection
653 a BSI
653 a kidney transplant
7001 a Perez-Nadales, Elenau Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Cordoba, Spain.4 aut
7001 a Perez-Galera, Salvadoru Virgen Macarena Univ Hosp, Clin Unit Internal Med, Seville, Spain.4 aut
7001 a Fernandez-Ruiz, Mariou Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Complutense, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Unit Infect Dis, 12 Octubre Univ Hosp, Madrid, Spain.4 aut
7001 a Carratala, Jordiu Univ Barcelona, Bellvitge Univ Hosp, Bellvitge Biomed Res Inst IDIBELL, Dept Infect Dis, Barcelona, Spain.4 aut
7001 a Oriol, Isabelu Univ Barcelona, Bellvitge Univ Hosp, Bellvitge Biomed Res Inst IDIBELL, Dept Infect Dis, Barcelona, Spain.4 aut
7001 a Cordero, Elisau Virgen del Rocio Univ Hosp, Clin Unit Infect Dis Microbiol & Prevent Med, Seville, Spain.4 aut
7001 a Antonio Lepe, Joseu Virgen del Rocio Univ Hosp, Clin Unit Infect Dis Microbiol & Prevent Med, Seville, Spain.4 aut
7001 a Tan, Ban Hocku Singapore Gen Hosp, Dept Infect Dis, Singapore, Singapore.4 aut
7001 a Corbella, Laurau Univ Complutense, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Unit Infect Dis, 12 Octubre Univ Hosp, Madrid, Spain.4 aut
7001 a Paul, Micalu Rambam Hlth Care Campus, Infect Dis Inst, Haifa, Israel.4 aut
7001 a Natera, Alejandra M.u Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Cordoba, Spain.4 aut
7001 a David, Miruna D.u Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England.4 aut
7001 a Montejo, Miguelu Cruces Univ Hosp, Infect Dis Unit, Bilbao, Spain.4 aut
7001 a Iyer, Ranganathan N.u Global Hosp, Clin Microbiol Identificat & Infect Control, Hyderabad, India.4 aut
7001 a Pierrotti, Ligia Camerau Univ Sao Paulo, Hosp Clin, Infect Dis Div, Med Sch, Sao Paulo, Brazil.4 aut
7001 a Merino, Esperanzau Gen Univ Hosp Alicante, Unit Infect Dis, ISABIAL, Alicante, Spain.4 aut
7001 a Steinke, Seema Mehtau Johns Hopkins Univ, Sch Med, Baltimore, MD USA.4 aut
7001 a Rana, Meenakshi M.u Icahn Sch Med Mt Sinai, New York, NY 10029 USA.4 aut
7001 a Munoz, Patriciau Univ Complutense Madrid, Serv Microbiol Clin & Enfermedades Infecciosas, Hosp Gen Univ Gregorio Maranon,CIBER Enfermedades, Inst Invest Sanitaria Gregorio Maranon,Fac Med, Madrid, Spain.4 aut
7001 a Mularoni, Alessandrau IRCCS ISMETT, Palermo, Italy.4 aut
7001 a van Delden, Christianu Univ Hosp Geneva, Unit Transplant Infect Dis, Geneva, Switzerland.;Swiss Transplant Cohort Study STCS, Geneva, Switzerland.4 aut
7001 a Grossi, Paolo Antoniou Univ Insubria, Varese Natl Ctr Transplantat, Dept Med & Surg, Infect Dis Sect, Rome, Italy.4 aut
7001 a Seminari, Elena Mariau Fdn IRCCS Policlin San Matteo Pavia, Div Infect Dis, Pavia, Italy.4 aut
7001 a Gunseren, Filizu Akdeniz Univ, Dept Infect Dis & Clin Microbiol, Fac Med, Antalya, Turkey.4 aut
7001 a Lease, Erika D.u Univ Washington, Div Pulm Crit Care & Sleep Med, Seattle, WA 98195 USA.4 aut
7001 a Roilides, Emmanuelu Aristotle Univ Thessaloniki, Sch Hlth Sci, Hippokrat Gen Hosp, Fac Med,Infect Dis Unit, Thessaloniki, Greece.;Aristotle Univ Thessaloniki, Sch Hlth Sci, Hippokrat Gen Hosp, Fac Med,Dept Pediat 3, Thessaloniki, Greece.4 aut
7001 a Fortun, Jesusu Ramon y Cajal Univ Hosp, Madrid, Spain.4 aut
7001 a Arslan, Handeu Bakent Univ, Sch Med, Ankara, Turkey.4 aut
7001 a Coussement, Julienu Univ Libre Bruxelles, Div Infect Dis, CUB Hop Erasme, Brussels, Belgium.4 aut
7001 a Tufan, Zeliha Kocaku Ankara Yildirim Beyazit Univ, Infect Dis & Clin Microbiol Dept, Med Sch, Ankara, Turkey.4 aut
7001 a Pilmis, Benoitu Paris Descartes Univ, Necker Enfants Malad Univ Hosp, AP HP,Inst Imagine, Dept Infect Dis & Trop Med,Ctr Infectiol Necker P, Paris, France.4 aut
7001 a Rizzi, Marcou ASST Papa Giovanni XXIII, Infect Dis Unit, Bergamo, Italy.4 aut
7001 a Loeches, Belenu Hosp La Paz, Infect Dis Unit, Madrid, Spain.4 aut
7001 a Eriksson, Britt-Marie,c Docent,d 1952-u Uppsala universitet,Infektionssjukdomar4 aut0 (Swepub:uu)breri424
7001 a Abdala, Edsonu Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.4 aut
7001 a Soldani, Fabiou Azienda Osped Univ Integrata Verona, Dept Med, Infect Dis Unit, Verona, Italy.4 aut
7001 a Lowman, Warrenu Univ Witwatersrand, Fac Hlth Sci, Wits Donald Gordon Med Ctr, Pathcare Vermaak, Johannesburg, South Africa.4 aut
7001 a Clemente, Wanessa Trindadeu Univ Fed Minas Gerais HC UFMG, Hosp Clin, Fac Med, Inst Alfa Gastroenterol,Grp Transplante Figado, Belo Horizonte, MG, Brazil.4 aut
7001 a Bodro, Martau Univ Barcelona, Hosp Clin IDIBAPS, Infect Dis Dept, Barcelona, Spain.4 aut
7001 a Carmen Farinas, Mariau Univ Cantabria, Hosp Univ Marques de Valdecilla, Infect Dis Unit, Santander, Spain.4 aut
7001 a Kazak, Esrau Uludag Univ, Bursa, Turkey.4 aut
7001 a Martinez-Martinez, Luisu Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Dept Microbiol,Clin Unit Microbiol, Cordoba, Spain.4 aut
7001 a Maria Aguado, Joseu Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Complutense, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Unit Infect Dis, 12 Octubre Univ Hosp, Madrid, Spain.4 aut
7001 a Torre-Cisneros, Julianu Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Clin Unit Infect Dis, Cordoba, Spain.4 aut
7001 a Pascual, Alvarou Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Seville, Virgen Macarena Univ Hosp, Inst Biomed Seville, Clin Unit Infect Dis & Microbiol, Seville, Spain.4 aut
7001 a Rodriguez-Bano, Jesusu Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Seville, Virgen Macarena Univ Hosp, Inst Biomed Seville, Clin Unit Infect Dis & Microbiol, Seville, Spain.4 aut
7102 a Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Seville, Virgen Macarena Univ Hosp, Inst Biomed Seville, Clin Unit Infect Dis & Microbiol, Seville, Spain.b Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Cordoba, Spain.4 org
7730 t Antimicrobial Agents and Chemotherapyd : American Society for Microbiologyg 65:11q 65:11x 0066-4804x 1098-6596
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-470107
8564 8u https://doi.org/10.1128/AAC.01102-21

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy